对尼尔瓦迪-血红蛋白相互作用的分子洞察:构造动态和结合机制
Mohd Shahnawaz Khan1, Md Tabish Rehman2, Nojood Al-Twaijry1
1Department of Biochemistry, College of Science, King Saud University Riyadh 11451 Saudi Arabia moskhan@ksu.edu.sa.
RSC advances
|November 13, 2025
概括
尼尔瓦迪平与血红蛋白 (Hb) 形成稳定的复合体,主要是通过疏水性相互作用. 这种结合不会改变Hb的结构,这表明血红蛋白可能充当药物储存库.
科学领域:
- 生物化学和分子生物学
- 药理学 药理学是指药理学的学科.
- 生物物理学的生物物理.
背景情况:
- 了解药物蛋白相互作用对于预测药物行为和安全至关重要.
- 血红蛋白 (Hb) 是循环中的小分子的潜在结合标.
研究的目的:
- 描述尼尔瓦迪和血红蛋白 (Hb) 之间的结合相互作用.
- 阐明这个复杂的形成的热力学和结构基础.
- 评估尼尔瓦迪结合对Hb结构完整性的影响.
主要方法:
- 使用光谱技术 (索雷特带吸收,光光谱,FRET) 来研究尼尔瓦迪-Hb的结合.
- 热力学分析 (van't Hoff) 确定了约束参数.
- 分子对接和分子动力学 (MD) 模拟研究了结合姿势和复杂稳定性.
主要成果:
- 尼尔瓦迪平与Hb结合,其结合率为1:1和高度亲和力 (K_SV ~10^4 M^-1).
- 疏水性相互作用驱动了自发的,稳定的复合体形成 (ΔH° > 0, ΔS° > 0, ΔG° < 0).
- 分子模拟证实了一个稳定的复合体,Hb.的结构干扰最小.
结论:
- 尼尔瓦迪平与Hb形成一个稳定的,疏水驱动的复合体,而不会影响其全球结构.
- Hb可以作为循环中的尼尔瓦迪的暂时储存器.
- 这项研究为分析小分子与血液蛋白的相互作用提供了一个框架,有助于药物开发和安全性评估.
相关概念视频
Drug Binding to Blood Components
483
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
483
Protein-Drug Binding: Mechanism and Kinetics
1.6K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.6K
Factors Affecting Protein-Drug Binding: Drug Interactions
539
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
539
The Equilibrium Binding Constant and Binding Strength
14.8K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
14.8K
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
569
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
569
Factors Affecting Protein-Drug Binding: Drug-Related Factors
444
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
444


